Advanced search
1 file | 1.82 MB Add to list

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment?: biological, pharmacological and clinical aspects

Author
Organization
Keywords
NSCLC, Erlotinib, GROWTH-FACTOR RECEPTOR, ACQUIRED-RESISTANCE, STANDARD CHEMOTHERAPY, Lung cancer, Gefitinib, Tyrosine kinase, EGFR, PHASE-III TRIAL, FAILED PREVIOUS CHEMOTHERAPY, PREVIOUSLY TREATED PATIENTS, OPEN-LABEL, TYROSINE-KINASE, PULMONARY ADENOCARCINOMA, MOLECULAR PREDICTORS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.82 MB

Citation

Please use this url to cite or link to this publication:

MLA
Bronte, Giuseppe, Christian Rolfo, Elisa Giovannetti, et al. “Are Erlotinib and Gefitinib Interchangeable, Opposite or Complementary for Non-small Cell Lung Cancer Treatment?: Biological, Pharmacological and Clinical Aspects.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 89.2 (2014): 300–313. Print.
APA
Bronte, G., Rolfo, C., Giovannetti, E., Cicero, G., Pauwels, P., Passiglia, F., Castiglia, M., et al. (2014). Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment?: biological, pharmacological and clinical aspects. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 89(2), 300–313.
Chicago author-date
Bronte, Giuseppe, Christian Rolfo, Elisa Giovannetti, Giuseppe Cicero, Patrick Pauwels, Francesco Passiglia, Marta Castiglia, et al. 2014. “Are Erlotinib and Gefitinib Interchangeable, Opposite or Complementary for Non-small Cell Lung Cancer Treatment?: Biological, Pharmacological and Clinical Aspects.” Critical Reviews in Oncology Hematology 89 (2): 300–313.
Chicago author-date (all authors)
Bronte, Giuseppe, Christian Rolfo, Elisa Giovannetti, Giuseppe Cicero, Patrick Pauwels, Francesco Passiglia, Marta Castiglia, Sergio Rizzo, Francesca Lo Vullo, Eugenio Fiorentino, Jan Van Meerbeeck, and Antionio Russo. 2014. “Are Erlotinib and Gefitinib Interchangeable, Opposite or Complementary for Non-small Cell Lung Cancer Treatment?: Biological, Pharmacological and Clinical Aspects.” Critical Reviews in Oncology Hematology 89 (2): 300–313.
Vancouver
1.
Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment?: biological, pharmacological and clinical aspects. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2014;89(2):300–13.
IEEE
[1]
G. Bronte et al., “Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment?: biological, pharmacological and clinical aspects,” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 89, no. 2, pp. 300–313, 2014.
@article{4342938,
  author       = {Bronte, Giuseppe and Rolfo, Christian and Giovannetti, Elisa and Cicero, Giuseppe and Pauwels, Patrick and Passiglia, Francesco and Castiglia, Marta and Rizzo, Sergio and Lo Vullo, Francesca and Fiorentino, Eugenio and Van Meerbeeck, Jan and Russo, Antionio},
  issn         = {1040-8428},
  journal      = {CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY},
  keywords     = {NSCLC,Erlotinib,GROWTH-FACTOR RECEPTOR,ACQUIRED-RESISTANCE,STANDARD CHEMOTHERAPY,Lung cancer,Gefitinib,Tyrosine kinase,EGFR,PHASE-III TRIAL,FAILED PREVIOUS CHEMOTHERAPY,PREVIOUSLY TREATED PATIENTS,OPEN-LABEL,TYROSINE-KINASE,PULMONARY ADENOCARCINOMA,MOLECULAR PREDICTORS},
  language     = {eng},
  number       = {2},
  pages        = {300--313},
  title        = {Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment?: biological, pharmacological and clinical aspects},
  url          = {http://dx.doi.org/10.1016/j.critrevonc.2013.08.003},
  volume       = {89},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: